TapewireFind a company

person · Reporting owner

Sabag Mark

Disclosed activity across 1 company

Tapewire entity
50096
SEC CIK
0001721442

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063See "Remarks"May 01, 2026May 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date May 01, 2026 · Filed May 04, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect80,760 Reported balance After 2026-05-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-05-01 · Sale · Disposed 144,180 · Balance 80,760

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.935 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.935 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 01, 2026 Filed May 4, 2026 20:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 144,180 $34.99 $5,045,117.72
Disclosure

SEC source: 0001193125-26-203928 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,760

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.935 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 17, 2026 Filed Mar 19, 2026 20:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 62,102 $30.14 $1,871,816.38
Disclosure

SEC source: 0001193125-26-115929 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,940

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.115 to $30.215, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 20:23 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 15,723 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-098582 · ownership.xml · derivative · entry 2

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,170

Underlying: Ordinary Shares · 15,723 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 15,723 vested on March 5, 2026, 15,723 vesting on each of March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029.

F3 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 15,723 vested on March 5, 2026, 15,723 vesting on each of March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 20:23 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 15,723 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-098582 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 287,042

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 30,385 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-096538 · ownership.xml · derivative · entry 5

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,385

Underlying: Ordinary Shares · 30,385 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2026, with 7,596 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 7,597 vesting on March 4, 2030.

F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2026, with 7,596 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 7,597 vesting on March 4, 2030.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 18,601 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-096538 · ownership.xml · derivative · entry 4

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,202

Underlying: Ordinary Shares · 18,601 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 18,601 vested on each of March 4, 2025 and March 4, 2026, and 18,601 vesting on each of March 4, 2027 and March 4, 2028.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 18,601 vested on each of March 4, 2025 and March 4, 2026, and 18,601 vesting on each of March 4, 2027 and March 4, 2028.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 33,512 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-096538 · ownership.xml · derivative · entry 3

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 33,512 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.

F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 18,601 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-096538 · ownership.xml · nonDerivative · entry 2

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 271,319

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 33,512 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-096538 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 252,718

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 141,478 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-093938 · ownership.xml · derivative · entry 4

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 141,478 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

F4 · derivative.expiration_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 24,900 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-093938 · ownership.xml · derivative · entry 3

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,901

Underlying: Ordinary Shares · 24,900 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2024, with 24,900 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2024, with 24,900 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 141,478 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-093938 · ownership.xml · nonDerivative · entry 2

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 219,206

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 24,900 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-093938 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,728

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 141,478 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-029312 · ownership.xml · derivative · entry 1

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,478

Underlying: Ordinary Shares · 141,478 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026.

F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 21:06 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionStock Options (right to buy) · Derivative 118,724 $0.00 Strike: $18.61 $0.00
Disclosure

SEC source: 0001193125-25-315923 · ownership.xml · derivative · entry 4

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 118,724 shares

Expires 2028-02-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Stock options were granted on February 9, 2018, with 39,574 vested on each of February 9, 2020, February 9, 2021 and February 9, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 21:06 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 98,168 $28.70 $2,817,676.84
Disclosure

SEC source: 0001193125-25-315923 · ownership.xml · nonDerivative · entry 3

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,828

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.675 to $28.745, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 21:06 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 118,724 $28.75 $3,413,077.55
Disclosure

SEC source: 0001193125-25-315923 · ownership.xml · nonDerivative · entry 2

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,996

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.705 to $28.845, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 21:06 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 118,724 $18.61 $2,209,453.64
Disclosure

SEC source: 0001193125-25-315923 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 269,720

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
May 08, 2025 Filed May 12, 2025 20:00 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 337,915 $18.04 $6,097,304.47
Disclosure

SEC source: 0000950170-25-069132 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,996

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.865 to $18.265, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 62,893 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-035512 · ownership.xml · derivative · entry 3

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,893

Underlying: Ordinary Shares · 62,893 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 15,723 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029.

F4 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 15,723 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 23,765 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-035512 · ownership.xml · derivative · entry 2

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 23,765 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 23,765 vested on March 5, 2025.

F3 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 23,765 vested on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 23,765 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-035512 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 488,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 183,169 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-034617 · ownership.xml · derivative · entry 6

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 183,169 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025.

F5 · derivative.expiration_date: Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 18,601 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-034617 · ownership.xml · derivative · entry 5

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,803

Underlying: Ordinary Shares · 18,601 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 18,601 vested on March 4, 2025, and 18,601 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 18,601 vested on March 4, 2025, and 18,601 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 33,512 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-034617 · ownership.xml · derivative · entry 4

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,512

Underlying: Ordinary Shares · 33,512 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026.

F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 183,169 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-034617 · ownership.xml · nonDerivative · entry 3

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 465,146

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 18,601 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-034617 · ownership.xml · nonDerivative · entry 2

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 281,977

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 33,512 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-034617 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 263,376

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:16 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 24,900 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-033597 · ownership.xml · derivative · entry 2

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,801

Underlying: Ordinary Shares · 24,900 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 24,900 vested on each of March 3, 2024 and March 3, 2025, 24,900 vesting on March 3, 2026, and 24,901 vesting on March 3, 2027.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 24,900 vested on each of March 3, 2024 and March 3, 2025, 24,900 vesting on March 3, 2026, and 24,901 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:16 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 24,900 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-033597 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 229,864

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 177,626 $16.25 $2,886,564.60
Disclosure

SEC source: 0000950170-25-021151 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · See "Remarks"

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 204,964

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.21 to $16.335, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
January 28, 2025 Filed Jan 30, 2025 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 183,169 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-011064 · ownership.xml · derivative · entry 1

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 183,169

Underlying: Ordinary Shares · 183,169 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2025.

F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2025.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 58,133 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-027959 · ownership.xml · derivative · entry 5

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 58,133 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.

F5 · derivative.expiration_date: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 23,764 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-027959 · ownership.xml · derivative · entry 4

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,765

Underlying: Ordinary Shares · 23,764 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025.

F4 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 100,000 $13.52 $1,352,090.00
Disclosure

SEC source: 0000950170-24-027959 · ownership.xml · nonDerivative · entry 3

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 382,590

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 58,133 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-027959 · ownership.xml · nonDerivative · entry 2

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 482,590

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 23,764 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-027959 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 424,457

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 74,404 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-025917 · ownership.xml · derivative · entry 5

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,404

Underlying: Ordinary Shares · 74,404 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 18,601 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027, and March 4, 2028.

F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 18,601 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027, and March 4, 2028.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 33,512 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-025917 · ownership.xml · derivative · entry 4

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,024

Underlying: Ordinary Shares · 33,512 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 33,512 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-025917 · ownership.xml · nonDerivative · entry 2

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,693

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2024 Filed Mar 5, 2024 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 24,900 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-025917 · ownership.xml · derivative · entry 3

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,701

Underlying: Ordinary Shares · 24,900 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2024 Filed Mar 5, 2024 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 24,900 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-025917 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 367,181

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 11:52 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 20,599 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-023528 · ownership.xml · derivative · entry 2

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 20,599 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 20,598 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024.

F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 20,598 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 11:52 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 20,599 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-023528 · ownership.xml · nonDerivative · entry 1

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 342,281

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
January 30, 2024 Filed Feb 1, 2024 12:18 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 58,133 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-009610 · ownership.xml · derivative · entry 1

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,133

Underlying: Ordinary Shares · 58,133 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024.

F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2023 Filed Mar 7, 2023 21:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 23,764 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016714 · doc4.xml · derivative · entry 7

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,529

Underlying: Ordinary Shares · 23,764 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022 and March 5, 2023, 23,764 vesting on March 5, 2024, and 23,765 vesting on March 5, 2025.

F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022 and March 5, 2023, 23,764 vesting on March 5, 2024, and 23,765 vesting on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2023 Filed Mar 7, 2023 21:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 23,764 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016714 · doc4.xml · nonDerivative · entry 3

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 321,682

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 33,512 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016714 · doc4.xml · derivative · entry 6

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,536

Underlying: Ordinary Shares · 33,512 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026.

F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 15,921 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016714 · doc4.xml · derivative · entry 5

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 15,921 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 15,920 vested on each of March 4, 2021 and March 4, 2022, and 15,921 vested on March 4, 2023.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 15,920 vested on each of March 4, 2021 and March 4, 2022, and 15,921 vested on March 4, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 15,921 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016714 · doc4.xml · nonDerivative · entry 2

Sabag Mark · CIK 0001721442 · EVP, International Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 297,918

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.